All-Oral AML Routine Reveals Promise for Older, Unfit Sufferers

An all-oral mixture of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) used to be active and precise in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive chemotherapy, results of a phase II trial commended.

In the continuing, single-center explore, 64% of the 47 evaluable newly diagnosed patients responded to the mixture, with full remissions or full remissions with incomplete restoration (CR/CRi) in 57%, reported Farhad Ravandi, MD, of MD Anderson Most cancers Heart in Houston, and colleagues.

In 13 patients with relapsed or refractory illness, 46% responded, including CR/CRi’s in all of these patients, in accordance to findings printed in Lancet Haematology.

The protection profile consisted mostly of gastrointestinal aspect effects, myelosuppression, and infections, which the researchers talked about had been “in accordance with expectations” for the mixture of decitabine-cedazuridine (a chemotherapy plus a cytidine deaminase inhibitor) plus venetoclax (a BCL-inhibitor).

The commonest grade ≥3 cure-emergent destructive occasions (AEs) had been febrile neutropenia (18%), pneumonia (13%), respiratory failure (8%), bacteremia (6%), and sepsis (6%). Three deaths from sepsis, gastrointestinal hemorrhage, and respiratory failure came about in patients in remission and had been regarded as to be potentially cure connected.

If the present findings are confirmed in a multicenter phase III trial, the regimen “would per chance perchance per chance develop into the contemporary frequent of care” for these older AML patients who are ineligible for intensive chemotherapy, wrote Anna Candoni, MD, of the University of Modena and Reggio Emilia in Italy, in an accompanying comment. “This contemporary total oral regimen would per chance be an additional and fundamental step forward in the cure of acute myeloid leukemia in older or unfit patients.”

Alternatively, Candoni cautioned that the infectious considerations noticed in the trial had been “no longer negligible.”

“It would per chance perchance per chance be fundamental for future total oral cure trials to pay particular consideration to the considerations with infectious considerations and hematological toxicity, by offering detailed data on the anti-infectious prophylaxis and its preventive raise out and on the valid utilize of granulocyte boost factors,” she added.

For the AE of myelosuppression, Ravandi and colleagues talked about that they “strongly lend a hand the utilize of triple anti-infective prophylaxis (i.e., antiviral, antibacterial, and mildew-active triazole antifungal) to gash these dangers” and illustrious that “even supposing the optimum length of venetoclax per cycle has no longer been obvious, these data counsel remissions would per chance perchance per chance even be maintained with shorter durations of venetoclax in patients who journey difficulties with myelosuppression.”

Oral venetoclax (400 mg) used to be given for 21 to 28 days of 28-day cycles, but a low cost in the length of venetoclax administration used to be wished for quite so much of patients beyond the principle cycle following remission. Beyond cycle five, most patients had been receiving both 5 or 7 days of venetoclax per cycle. (Decitabine (35 mg)/cedazuridine (100 mg) used to be given for the principle 5 days of every cycle.)

The phase II explore enrolled 62 patients with newly diagnosed AML who weren’t eligible for intensive chemotherapy or with relapsed or refractory AML. Reasons patients would per chance perchance per chance no longer gain chemotherapy integrated age (≥75 years), efficiency space (ECOG 2-3), or main comorbidities.

The cohort “used to be representative of an older acute myeloid leukemia population at excessive possibility of sorrowful outcomes,” Ravandi and colleagues noticed.

Contributors had a median age of 78 years, and 58% had been males, while 85% had been white, 6% had been Unlit, and 3% had been Asian. Sufferers had a different of harmful prognostic factors: 77% had an destructive European LeukemiaNet 2022 possibility classification, 39% beforehand had myelodysplastic syndromes, 19% beforehand failed cure with a hypomethylating agent, 16% had therapy-connected AML, and 18% had TP53 mutations.

With a median note-up of 18.3 months, median total survival (OS) reached 11.5 months in the newly diagnosed cohort. Amongst these with CR/CRi, the relapse-free survival reached 12 months and median length of response used to be 13.2 months.

In the relapsed or refractory community, median OS used to be 7.2 months, relapse-free survival used to be 4.6 months, and length of response used to be 5.4 months.

The main trial limitation used to be that it used to be performed at a single, substantial academic center with a comparatively tiny different of patients, in particular in the relapsed or refractory cohort, Ravandi and co-authors acknowledged.

However they illustrious that the frontline leads to this explore had been akin to these seen with varied venetoclax-primarily based completely mostly regimens, akin to azacitidine plus venetoclax in the VIALE-A trial. That explore established parenteral azacitidine plus venetoclax as the contemporary frequent of care in older or unfit patients, with a reported composite full remission fee of 66.4% and a median OS of 14.7 months.

“When compared with parenteral regimens, this absolutely oral regimen has the prospective advantages of less hospital visits and shorter inpatient stays. In turn, this may perchance probably perchance per chance consequence in improved quality of existence and preservation of purposeful space in older patients with acute myeloid leukemia or these with colossal comorbidities,” Ravandi’s community acknowledged.

  • author['full_name']

    Mike Bassett is a staff author focusing on oncology and hematology. He relies mostly in Massachusetts.


The trial used to be supported by a grant from MD Anderson Most cancers Heart, the Myelodysplastic Syndrome/Acute Myeloid Leukaemia Moon Shot, Leukemia SPORE, Taiho Oncology, and Astex Pharmaceuticals.

Ravandi disclosed relationships with Astex Pharmaceuticals and Taiho Oncology. Co-authors disclosed relationships with, and/or beef up from, a number of trade entities, including Astex Pharmaceuticals.

Candoni disclosed relationships with AbbVie, Astellas, Janssen, Jazz, Celgene, Gilead, Pfizer, Incyte, and Amgen.

Predominant Provide

The Lancet Haematology

Provide Reference: Bazinet A, et al “Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 explore” Lancet Haematol 2024; DOI: 10.1016/S2352-3026(24)00033-4.

Secondary Provide

The Lancet Haematology

Provide Reference: Candoni A “Utterly oral regimen with decitabine and cedazuridine plus venetoclax: a brand contemporary step forward for older or unfit patients with acute myeloid leukaemia” Lancet Haematol 2024; DOI: 10.1016/S2352-3026(24)00060-7.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button